Collegium Pharmaceutical (COLL) Change in Accured Expenses (2014 - 2026)
Collegium Pharmaceutical (COLL) posted quarterly Change in Accured Expenses of -$4.2 million for Q1 2026, up 76.51% year-over-year from -$2.4 million in Q1 2025, and down 138.79% quarter-over-quarter from $10.7 million in Q4 2025.
Collegium Pharmaceutical (COLL) Change in Accured Expenses (2014 - 2026) Analysis & Trends
Collegium Pharmaceutical's Change in Accured Expenses history runs 13 years deep, the most recent figure standing at -$4.2 million for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 76.51% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at $4.0 million (up 106.96% YoY), while the FY2025 annual figure was -$9.5 million, up 75.98% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at -$4.2 million, down from $10.7 million in the prior quarter.
- The five-year high for Change in Accured Expenses was $22.4 million in Q4 2024, with the low at -$62.9 million in Q3 2024.
- The 5-year median for Change in Accured Expenses is -$821000.0 (2022), against an average of -$3.7 million.
- Peak annual rise in Change in Accured Expenses reached 1635.09% in 2025, while the deepest fall reached 2777.73% in 2025.
- Collegium Pharmaceutical's Change in Accured Expenses stood at $13.6 million in 2022, then tumbled by 62.42% to $5.1 million in 2023, then soared by 339.04% to $22.4 million in 2024, then tumbled by 52.26% to $10.7 million in 2025, then sank by 138.79% to -$4.2 million in 2026.
- Business Quant data shows COLL's Change in Accured Expenses at -$4.2 million in Q1 2026, $10.7 million in Q4 2025, and -$8.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - | - |
| 10 | Collegium Pharmaceutical | 897.87 Mn | 748.55 Mn | 110.29 Mn | 12.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.28 Mn |
| Jun 30, 2026 | 12.28 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Mar 31, 2026 | -4.15 Mn |
| Dec 31, 2025 | 10.71 Mn |
| Dec 31, 2025 | 10.71 Mn |
| Sep 30, 2025 | -8.11 Mn |
| Sep 30, 2025 | -8.11 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Jun 30, 2025 | 5.59 Mn |
| Mar 31, 2025 | -17.67 Mn |
| Mar 31, 2025 | -17.67 Mn |
| Dec 31, 2024 | 22.42 Mn |
| Dec 31, 2024 | 22.42 Mn |
| Sep 30, 2024 | -62.93 Mn |
| Sep 30, 2024 | -62.93 Mn |
| Jun 30, 2024 | 322,000.00 |
| Jun 30, 2024 | 322,000.00 |
| Mar 31, 2024 | 660,000.00 |
| Mar 31, 2024 | 660,000.00 |